The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report

• Published in: Frontiers in oncology Vol. 13; p. 1096955
• Main Authors: Mu, Chunyang, Shen, Junyi, Zhu, Xinrui, Peng, Wei, Zhang, Xiaoyun, Wen, Tianfu
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16.05.2023
• Subjects: combination therapy; lenvatinib; Oncology; programmed death-1 antibody; recurrent hepatocellular carcinoma; trans-arterial chemoembolization; recurrent hepatocellular carcinoma; combination therapy; lenvatinib; trans-arterial chemoembolization; programmed death-1 antibody

To explore the safety and efficacy of lenvatinib in combination with trans-arterial chemoembolization (TACE) and programmed death receptor 1 (PD-1) antibody in the treatment of unresectable recurrent hepatocellular carcinoma (urHCC). The clinical data of 16 patients with unresectable recurrent hepat...